Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin + Pembrolizumab in Advanced Urothelial Cancer
NCT04223856Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Mar 2020
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 25
01
Overview
A Phase 3 trial of enfortumab vedotin, pembrolizumab in urothelial carcinoma (UC), sponsored by Astellas Pharma. Started Mar 2020; status: active, not recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04223856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223856.